Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

John Andrew Stauffer

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0126-0301; OpenAlex author ID A5023058357. Sources: OpenAlex.

Their work

Papers
22 (first author 3, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
61
Papers, trials and grants by year

2013: 2 papers · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: 1 paper · 2019: 2 papers · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers · 2024: 2 papers · 2025: 1 paper · 2026: 5 papers

Papers 22

  1. Disparities in Pancreatic Cancer Survival: The Overlooked Role of Demographic and Socioeconomic Factors. Co-author DOI 10.1002/jso.70377↗
  2. Factors Associated with Improved Survival for Stage I and II Pancreatic Adenocarcinoma Utilizing the National Cancer Database. Co-author DOI 10.1007/s12029-026-01545-4↗
  3. Nationwide Trends in Neoadjuvant Chemotherapy Utilization for Pancreatic Adenocarcinoma From 2012 to 2021. Last author DOI 10.1016/j.jss.2026.09.037↗
  4. Intraoperative radiation therapy during pancreatectomy for borderline and locally advanced pancreatic cancer: A propensity-matched analysis. Last author DOI 10.1016/j.surg.2026.110293↗
  5. Redefining Upfront Resectable Pancreatic Ductal Adenocarcinoma: Should Vein Abutment Matter? Co-author DOI 10.6004/jnccn.2025.7097↗
  6. Risk factors in predicting radiologically occult metastatic disease from pancreatic ductal adenocarcinoma: a single-institution experience with routine preoper… Last author DOI 10.1016/j.gassur.2025.102214↗
  7. Laparoscopic distal pancreatectomy for pancreatic cancer: an overview of evaluation and treatment strategies. First author DOI 10.21037/jgo-23-784↗
  8. Exploring the complexities of metachronous primary tumors after surgically managed pancreatic cancer-why lightning strikes twice. First author DOI 10.21037/jgo-24-448↗
  9. Efficacy of Immune Checkpoint Inhibition and Cytotoxic Chemotherapy in Mismatch Repair-Deficient and Microsatellite Instability-High Pancreatic Cancer: Mayo Cl… Co-author DOI 10.1200/po.22.00706↗
  10. Targeting KRAS in pancreatic adenocarcinoma: Progress in demystifying the holy grail. Co-author DOI 10.5306/wjco.v14.i8.285↗
  11. Comparing Post-Operative Outcomes of Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: Neoadjuvant Therapy Versus Surgery First Approach. Last author DOI 10.1177/00031348221087900↗
  12. The Increasing Proportion of Early-Stage Pancreatic Cancer between 2004-2013: A SEER Analysis. Co-author DOI 10.1080/07357907.2021.1888386↗
  13. Minimally Invasive Approaches to Pancreatic Cancer. Co-author DOI 10.1016/j.soc.2018.11.006↗
  14. Intraoperative Irreversible Electroporation in Locally Advanced Pancreatic Cancer: A Guide for the Interventional Radiologist. Co-author DOI 10.1055/s-0039-1697640↗
  15. Survival of Patients with Oligometastatic Pancreatic Ductal Adenocarcinoma Treated with Combined Modality Treatment Including Surgical Resection: A Pilot Study. Co-author DOI 10.1089/pancan.2018.0011↗
  16. Laparoscopic versus open pancreaticoduodenectomy for pancreatic adenocarcinoma: long-term results at a single institution. Co-author DOI 10.1007/s00464-016-5222-1↗
  17. Feasibility of pancreatectomy following high-dose proton therapy for unresectable pancreatic cancer. Co-author DOI 10.4240/wjgs.v9.i4.103↗
  18. Laparoscopic Versus Open Distal Pancreatectomy for Pancreatic Adenocarcinoma. Co-author DOI 10.1007/s00268-016-3412-6↗
  19. Pancreatic exocrine insufficiency in pancreatic cancer: A review of the literature. Co-author DOI 10.1016/j.dld.2015.06.015↗
  20. ZIP4 is a novel diagnostic and prognostic marker in human pancreatic cancer: a systemic comparison between EUS-FNA and surgical specimens. Co-author DOI 10.2174/1566524013666131217112921↗
  21. Minimally invasive surgical techniques for pancreatic cancer: ready for prime time? First author DOI 10.1007/s00534-013-0614-2↗
  22. Risk of gastric or peritoneal recurrence, and long-term outcomes, following pancreatic cancer resection with preoperative endosonographically guided fine needl… Co-author DOI 10.1055/s-0033-1344216↗

Closest collaborators

The 25 strongest of 61 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Katherine E. Poruk · 6 shared papers, 2025–2026 · strength 1.76
  2. Zhi Ven Fong · 4 shared papers, 2026 · strength 1.17
  3. Cornelius A. Thiels · 4 shared papers, 2026 · strength 1.17
  4. Horacio J. Asbun · 9 shared papers, 2013–2024 · strength 0.95
  5. Alfredo Verastegui · 3 shared papers, 2025–2026 · strength 0.89
  6. Sibi Krishna Thiyagarajan · 2 shared papers, 2025–2026 · strength 0.59
  7. Jared Mount · 1 shared paper, 2024 · strength 0.46
  8. Kabir Mody · 4 shared papers, 2016–2021 · strength 0.40
  9. Massimo Raimondo · 5 shared papers, 2013–2021 · strength 0.38
  10. Domenech Asbun · 1 shared paper, 2024 · strength 0.36
  11. Michael S. Rutenberg · 2 shared papers, 2017–2026 · strength 0.35
  12. Mohamad Bassam Sonbol · 2 shared papers, 2023 · strength 0.33
  13. Jason Scott Starr · 2 shared papers, 2023 · strength 0.33
  14. Hani M. Babiker · 2 shared papers, 2023 · strength 0.33
  15. Tanios Bekaii‐Saab · 2 shared papers, 2023 · strength 0.33
  16. Jason Pieri · 1 shared paper, 2026 · strength 0.32
  17. Michael B. Wallace · 4 shared papers, 2013–2021 · strength 0.31
  18. Christiana Youssef · 1 shared paper, 2026 · strength 0.30
  19. Arielle Jacover · 1 shared paper, 2026 · strength 0.29
  20. Po Hong Tan · 1 shared paper, 2026 · strength 0.24
  21. Nabil Wasif · 1 shared paper, 2026 · strength 0.24
  22. Richard J. Bold · 1 shared paper, 2026 · strength 0.24
  23. Susanne Gray Warner · 1 shared paper, 2026 · strength 0.24
  24. Chee‐Chee Stucky · 1 shared paper, 2026 · strength 0.24
  25. Michael L. Kendrick · 1 shared paper, 2026 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.